Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onCARlytics
- Development stage
- Unknown
- Lead developer
- Imugene
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral, Intravenous
01
Overview
**onCARlytics** is an investigational CF33-based oncolytic vaccinia virus engineered to encode a non-signaling truncated human CD19 antigen. After preferentially infecting solid-tumor cells, the virus drives cell-surface CD19 expression before virus-mediated lysis, thereby making otherwise CD19-negative solid tumors susceptible to CD19-directed therapies such as blinatumomab and CD19 CAR-T cells. The program originated from CF33 technology developed at City of Hope and is being advanced by Imugene. In the Phase 1 OASIS study, onCARlytics is administered intravenously or intratumorally with blinatumomab in adults with advanced or metastatic solid tumors. ([announcements.asx.com.au](https://announcements.asx.com.au/asxpdf/20230519/pdf/05pvd7wk17w18v.pdf))
- Other names
- OnCARlytics
02
Targets
CD19t (Truncated CD19)
Beyond the preview
Go deeper on onCARlytics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onCARlytics.